CPT® Code 90649

1. Indications

The Human Papillomavirus (HPV) vaccine is indicated for the prevention of infections caused by specific types of HPV, particularly those associated with the development of cervical cancer and other HPV-related diseases. The following conditions and circumstances warrant the administration of this vaccine:

• Prevention of Cervical Cancer The vaccine is primarily indicated for individuals to prevent cervical cancer caused by high-risk HPV types 16 and 18.
• Prevention of Genital Warts The vaccine also helps in preventing the occurrence of genital warts caused by HPV types 6 and 11.
• Vaccination Before Sexual Activity It is recommended to administer the vaccine before the onset of sexual activity to ensure maximum efficacy in preventing HPV infection.

2. Procedure

The administration of the Human Papillomavirus vaccine involves a structured procedure that includes the following steps:

• Step 1: Patient Assessment Prior to vaccination, a thorough assessment of the patient’s medical history and any potential contraindications to the vaccine should be conducted. This includes evaluating any previous allergic reactions to vaccine components or other medical conditions that may affect vaccine administration.
• Step 2: Preparation of Vaccine The quadrivalent HPV vaccine (CPT® Code 90649) should be prepared according to the manufacturer's guidelines. This includes checking the vaccine's expiration date, ensuring proper storage conditions, and shaking the vial gently to mix the vaccine before drawing it into the syringe.
• Step 3: Administration of Vaccine The vaccine is administered intramuscularly, typically in the deltoid muscle of the upper arm. The injection site should be cleaned with an alcohol swab prior to administration to minimize the risk of infection. The healthcare provider should ensure that the vaccine is injected at the correct angle and depth to ensure proper delivery.
• Step 4: Post-Administration Monitoring After the vaccine is administered, the patient should be monitored for a short period to observe for any immediate adverse reactions. This is typically done for about 15 minutes, especially in individuals with a history of allergies.

3. Post-Procedure

Following the administration of the HPV vaccine, patients may experience mild side effects, which can include soreness at the injection site, low-grade fever, or fatigue. These effects are generally short-lived and resolve without intervention. It is important to inform patients about the need for follow-up doses as part of the three-dose schedule to ensure optimal immunity. Patients should also be advised to report any unusual or severe reactions to their healthcare provider. Additionally, educational materials regarding the importance of completing the vaccination series and the role of the HPV vaccine in cancer prevention should be provided to the patient.